Glaucoma specialists say they’re often referred post-cataract surgery patients experiencing an IOP spike, many of whom could be treated by the referring surgeon. EyeWorld spoke with two glaucoma specialists to get their insights on what to watch for and management of these cases.
While the treatment mainstays for lowering and/or maintaining a target IOP are achieved with surgery, laser, or pharmaceuticals, patients often ask what else they can do. Several physicians spoke to EyeWorld about lifestyle changes that they recommend as an addition to traditional glaucoma therapies.
Steroid-induced glaucoma can present a number of issues, most notably increased IOP. Several ophthalmologists discussed identifying when and why this occurs and how to react to help improve the pressure.
Pseudoexfoliation syndrome is a systemic, age-related disease, with patients needing more frequent monitoring due to an increased risk of developing secondary open angle glaucoma from the condition. Two physicians provided their perspectives on the condition and advice for its identification, management, and considerations for surgery.
➤ NDA submitted for epithelium-on crosslinking therapy ➤ Positive results in Phase 2 trial for first-in-class therapy for acute optic neuritis ➤ Study: long-term, real-world findings evaluating standalone canaloplasty and trabeculotomy ➤ Phase 1b study evaluating sozinibercept for DME published ➤ Phase 2 study for topical dry AMD therapy begins ➤ FDA clears IND for gene therapy targeting Stargardt disease ➤ ASCRS news and events
In June 2024, the FDA approved the FSYX Ocular Pressure Adjusting Pump by Balance Ophthalmics, making it the first non-surgical, non-pharmaceutical, IOP-lowering therapy for patients with open angle glaucoma. Physicians shared how they are excited about being able to lower IOP safely in normal tension glaucoma patients with accompanying nocturnal IOP elevations.
➤ Study: ocular manifestations of Mpox ➤ ‘World’s first’ spiral IOL designed with artificial intelligence ➤ First-in-human implantation of wireless IOP sensor ➤ Final patient visit for Phase 2 wet AMD treatment trial ➤ Enrollment, dosing complete for Phase 1 AMD, DME therapy ➤ ASCRS news and events
➤ Topline results from trial for biologic eye drop for dry eye ➤ First patient dosed in Phase 3 trial evaluating oral non-opioid sedation ➤ First patient dosed in retinitis pigmentosa gene therapy trial ➤ Clinical program for IOP-lowering drug discontinued ➤ ASCRS news and events
One physician shared how switching out the typical top on a glaucoma medication for the Nanodropper Adaptor, a screw-on cap that delivers a smaller drop of the medication, has helped her glaucoma patients from a compliance standpoint.